🇺🇸 FDA
Patent

US 8323617

Treatment of arthritis and other musculoskeletal disorders with crosslinked hyaluronic acid

granted A61KA61K31/573A61K31/728

Quick answer

US patent 8323617 (Treatment of arthritis and other musculoskeletal disorders with crosslinked hyaluronic acid) held by ANIKA THERAPEUTICS, INC. expires Mon Nov 29 2032 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
ANIKA THERAPEUTICS, INC.
Grant date
Tue Dec 04 2012 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Nov 29 2032 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
9
CPC classes
A61K, A61K31/573, A61K31/728, A61K31/729, A61K35/28